Skip to main content
Equibles
CMMB logo

CMMB · Chemomab Therapeutics Ltd.

Track CMMB — free

Use CMMB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CMMB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.18 +0.01 (+0.85%) At close · Oct 20
Rebalance outlook locked
Market Cap
$8.65M
Shares
7.33M
Volume · Oct 20 64.83K Avg daily vol (3M) 101.17K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.18 Open$1.24 Day$1.17–1.29 52W close$1.17–3.40 Avg vol 30d112K Short int11K · 0.1% float · 1.0d Short vol9% Last earningsMay 11, 2023 DataJan 2020–Oct 2026 Filing10-Q · May 11

Up next

Latest filing: 10-Q
filed May 11, 2023
Q1 2023 earnings call transcript
call held May 11, 2023

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-64.8%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −34%
below
Price vs 50-day avg −42%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −50%
trailing
6-month return −19%
trailing
YTD return −28%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
1 of 13 funds reported for Sep 30 · net +4.4K sh shares
Insider flow Distributing
Net -$6.5K over 90 days · 100% sells
Short interest Falling
0.14% of float · ▼ -87.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — mid 3-yr range
Squeeze score 21
low risk · 0–100
Fundamentals
Weak
EPS growth −54%
Y/Y
Free cash flow $-11.1M
Balance sheet $7.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 96%
annualized · 1-yr
Max drawdown −66%
past year
ATR 14.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−34% Bearish
Price vs 50-day avg
−42% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
1 of 13 funds reported for Sep 30 · net +4.4K sh shares
Insider flow Distributing
Net -$6.5K over 90 days · 100% sells
Short interest Falling
0.14% of float · ▼ -87.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
13 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $3
vs 200-day avg -34% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CMMB
Chemomab Therapeutics Ltd.
this stock
$8.65M -28.5% — — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
13
% held
5.2%
Reported
1 of 13
Top holder
CITADEL ADVISORS LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
10.5K
Days to cover
1.0d
Change
-71.4K sh
View
Short Volume
Short vol %
9%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
9.2K
Value
$20.3K
As of
Sep 25, 2026
View
Off-Exchange
Off-exchange %
63.5%
Week of
Sep 14, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$6.5K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-9.0M
EPS diluted
$0.02
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 19, 2026
This year
13

On October 16, 2026, Chemomab Therapeutics entered Amendment No. 2 to its Domestication Merger Agreement, reducing post-Merger Combined Company shares outstanding from 10,000,000 to 5,000,000, and amended the CVR Agreement to adjust CVR holder reporting rights and payment mechanics.

View
Proposed Sales
Value
$1.0M
Shares
500.0K
Filed
Sep 12, 2024
View
Exempt Offerings
Offering
$10.0M
Filed
Aug 9, 2024
View
Earnings & Events
Webcasts
Last webcast
May 11, 2023
View

Performance

5D 20D 120D MTD YTD
CMMB -4.8% -50.4% -19.2% -0.8% -28.5%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -3.7% -49.9% -27.3% -1.7% -41.3%
Key facts CIK 1534248 CUSIP 16385C203 13F (30d) 1 filings 1 filers Visit website Investor relations